Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9 and re: John Anderson. Androgen-deprivation therapy--It's all a matter of timing. Eur Urol 2008;53:869-71

Eur Urol. 2009 Feb;55(2):e40-2; author reply e45-6. doi: 10.1016/j.eururo.2008.08.039. Epub 2008 Aug 24.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Androgen Antagonists / therapeutic use*
  • Cell Division
  • Humans
  • Kinetics
  • Male
  • Multicenter Studies as Topic
  • Patient Selection
  • Prostate-Specific Antigen / analysis
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Randomized Controlled Trials as Topic
  • Reproducibility of Results

Substances

  • Androgen Antagonists
  • Prostate-Specific Antigen